Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
1 nm » 10 nm (Expand Search), 1 mm (Expand Search), 1 m (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
1 nm » 10 nm (Expand Search), 1 mm (Expand Search), 1 m (Expand Search)
-
681
-
682
Tonic nM DA stabilizes the timing of LP activity over the short term.
Published 2015“…<p><b>(A) Pyloric output is altered by 1mM 4AP</b>. Representative experiments showing the motor output at three time points for a preparation continuously superfused with 1mM 4AP (blue) or 1mM 4AP + 5nM DA (green) beginning at t = 0. …”
-
683
-
684
-
685
-
686
-
687
-
688
-
689
-
690
Sexual hormone signaling differs between FVB/N-resistant and C57BL/6J-susceptible strains.
Published 2019Subjects: -
691
-
692
-
693
-
694
-
695
-
696
-
697
-
698
-
699
-
700
VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival.
Published 2018“…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”